크레오에스지
Financials
Valuation Metrics
크레오에스지's Market Cap is ₩845B. At end of 2025 it was ₩972B. Ranked #1379 of 2,421 in KR market (top 57%), #777 of 1,640 on KOSDAQ (top 47%), #62 of 159 in Software & Services (top 39%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 84.49B KRW | KR#1,379/2,421 Sec#62/159 |
| Revenue | 11.91B KRW | KR#2,264/2,421 Sec#147/159 |
| Net Income | -3.18B KRW | KR—/2,421 Sec—/159 |
| Total Assets | 91.40B KRW | KR#1,850/2,421 Sec#73/159 |
| Net Assets | 47.55B KRW | KR#1,940/2,421 Sec#98/159 |
| Employees | 47 | KR#2,075/2,421 Sec#134/159 |
| Value | ||
| P/B | 1.78x | KR#1,863/2,421 Sec#117/159 |
| P/S | 7.09x | KR#2,217/2,421 Sec#145/159 |
| FCF Yield | -3.40% | KR—/2,421 Sec—/159 |
| Profitability | ||
| ROE | -6.68% | KR#1,853/2,421 Sec#119/159 |
| ROA | -3.47% | KR#1,859/2,421 Sec#116/159 |
| Op. Margin | -31.95% | KR#2,182/2,421 Sec#142/159 |
| Revenue Growth | 33.49% | KR#349/2,421 Sec#21/159 |
| Financial Health | ||
| Debt Ratio | 92.22% | KR#1,478/2,421 Sec#118/159 |
| Total Debt | 56.65B KRW | KR#963/2,421 Sec#19/159 |
| FCF | -2.87B KRW | KR#1,383/2,421 Sec#96/159 |
| Cash | 427.9M KRW | KR#2,368/2,421 Sec#156/159 |
| Current Ratio | 1.03x | KR#1,690/2,421 Sec#127/159 |
| Performance | ||
| 1Y Return | -7.60% | KR#907/2,421 Sec#39/159 |
| 1M Return | -38.95% | KR#2,371/2,421 Sec#156/159 |
| From 52W High | -66.76% | KR#2,109/2,421 Sec#133/159 |
| 1Y MDD | -67.45% | KR#1,861/2,421 Sec#108/159 |
| Trading | ||
| Volume | 203,986 shares | KR#482/2,421 Sec#31/159 |
| Trading Value | 853.2M KRW | KR#766/2,421 Sec#43/159 |
| Foreign Own. | 0.00% | KR—/2,421 Sec—/159 |
| Per Share | ||
| EPS | -160 KRW | KR—/2,421 Sec—/159 |
| BPS | 2,395 KRW | KR#1,978/2,421 Sec#119/159 |
Company Info
CreoSG, established in 1997 and KOSDAQ-listed in 2002, strengthened its solutions business through a 2005 merger and expanded real estate operations in 2024. The company has diversified its portfolio to include solutions for financial institutions, bio-business for infectious disease vaccine development, and real estate operation and rental management. Leveraging its experience in financial system implementation, it is expanding into manufacturing and service sectors. CreoSG also pursues vaccine research and development utilizing system migration and a universal new drug development platform. It is headquartered in Gangnam-gu, Seoul Metropolitan City.